1.	A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Phase: Phase III Type: Treatment Status: Active Age: 15 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TH-CR-406/SARC021, NCT01440088
2.	Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: BMT 0499 Solid, NCT00179816
3.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
4.	Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
5.	Aerosol IL-2 for Pulmonary Metastases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 12 and over Sponsor: Other Protocol IDs: 2010-0700, NCT01590069
6.	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
7.	Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas Phase: Phase II Type: Treatment Status: Active Age: 30 and under Sponsor: NCI, Other Protocol IDs: 05-326, Other, NCT00592293
8.	Paclitaxel + Bevacizumab (Avastin®) for the Treatment of Metastatic or Unresectable Angiosarcoma Phase: Phase II Type: Treatment Status: Active Age: 13 and over Sponsor: Other Protocol IDs: SARCOMA0006, SU-01202010-4743, 17755, NCT01055028
9.	Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor Phase: Phase II Type: Treatment Status: Active Age: 3 to 55 Sponsor: Other Protocol IDs: 2009-0528, NCT01277744
10.	Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Active Age: 15 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: INNO-206-P2-STS-01, NCT01514188
11.	Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 15 and over Sponsor: Other Protocol IDs: SOL-11130-L, NCI-2012-00052, IRB# 7943, NCT01532687
12.	A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: 0 to 40 Sponsor: Other Protocol IDs: J12106, NCT01804634
13.	Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Phase: Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 03-133, P30CA008748, MSKCC-03133, NCT00089245
14.	Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 and over Sponsor: Other Protocol IDs: 09-090, NCT01099644
15.	A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma Phase: Phase I Type: Treatment Status: Active Age: 4 to 55 Sponsor: NCI, Other Protocol IDs: UPCC 04511, NCT01343043
16.	Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: SorIrin1576, NCT01518413
17.	A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Phase: Phase I Type: Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: RADIANT, NCT01625351
18.	Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 13 months and over Sponsor: Other Protocol IDs: 12-116, NCT01662804
19.	Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 100 Sponsor: Other Protocol IDs: EPROST-20110462, NCT01803152
20.	Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000554417, JHOC-J0685, NA_00003073, J0685, NCT00499733
21.	Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 50 Sponsor: NCI Protocol IDs: NCI-2011-02005, ARST08P1, CDR0000663937, COG-ARST08P1, U10CA098543, NCT01055314
22.	Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor Phase: No phase specified Type: Treatment Status: Active Age: 1 to 29 Sponsor: Other Protocol IDs: 10-091, NCT01189643
23.	Auto Transplant for High Risk or Relapsed Solid Tumor Phase: No phase specified Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 2011OC057, MT2011-09C, NCT01505569